Serum fetuin-A levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes

Biomarkers

Volumn 18, Issue 2, 2013, Pages 160-164

  Zhao, Zi Wen ^a   Lin, Chao Gui ^a   Wu, Ling Zhen ^a   Luo, Yu Kun ^a   Fan, Lin ^a   Dong, Xian Feng ^a   Zheng, Hong ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Coronary artery disease; Diabetes; Fetuin A

Indexed keywords

FETUIN A;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL;

AGED; ALPHA-2-HS-GLYCOPROTEIN; BIOLOGICAL MARKERS; BLOOD PRESSURE; BODY MASS INDEX; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES;

EID: 84873904158     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.762806     Document Type: Article

References (23)

1. Bilgir O, Kebapcilar L, Bilgir F, et al. (2010). Decreased serum fetuin-A levels are associated with coronary artery diseases. Intern Med 49:1281-5.
2. Chen L, Magliano DJ, Zimmet PZ. (2011). The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat Rev Endocrinol 8:228-36.
3. Cohn PF, Fox KM, Daly C. (2003). Silent myocardial ischemia. Circulation 108:1263-77. (Pubitemid 37099998)
4. Gejyo F, Schmid K. (1981). Purification and characterization of the two forms of human plasma alpha 2HS-glycoprotein. Biochim Biophys Acta 671:78-84. (Pubitemid 12219606)
5. Haffner SM, Lehto S, Rönnemaa T, et al. (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-34. (Pubitemid 28350165)
6. Ix JH, Barrett-Connor E, Wassel CL, et al. (2011). The associations of fetuin-A with subclinical cardiovascular disease in communitydwelling persons: the Rancho Bernardo Study. J Am Coll Cardiol 58:2372-9.
7. Ix JH, Katz R, de Boer IH, et al. (2012). Fetuin-A is inversely associated with coronary artery calcification in community-living persons: the Multi-Ethnic Study of Atherosclerosis. Clin Chem 58:887-95.
8. Ix JH, Shlipak MG, Brandenburg VM, et al. (2006). Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 113:1760-7. (Pubitemid 43958469)
9. Laughlin GA, Cummins KM, Wassel CL, et al. (2012). The association of fetuin-A with cardiovascular disease mortality in older communitydwelling adults: the Rancho Bernardo study. J Am Coll Cardiol 59:1688-96.
10. Li W, Zhu S, Li J, et al. (2011). A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PLoS One 6:e16945.
11. Lim P, Collet JP, Moutereau S, et al. (2007). Fetuin-A is an independent predictor of death after ST-elevation myocardial infarction. Clin Chem 53:1835-40. (Pubitemid 47509678)
12. Mathews ST, Singh GP, Ranalletta M, et al. (2002). Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes 51:2450-8. (Pubitemid 34827393)
13. Mori K, Emoto M, Araki T, et al. (2007). Association of serum fetuin-A with carotid arterial stiffness. Clin Endocrinol (Oxf) 66:246-50. (Pubitemid 46096145)
14. Mori K, Ikari Y, Jono S, et al. (2010). Fetuin-A is associated with calcified coronary artery disease. Coron Artery Dis 21:281-5.
15. Reinehr T, Roth CL. (2008). Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab 93:4479-85. (Pubitemid 352789550)
16. Rittig K, Thamer C, Haupt A, et al. (2009). High plasma fetuin-A is associated with increased carotid intima-media thickness in a middleaged population. Atherosclerosis 207:341-2.
17. Shang FJ, Wang JP, Liu XT, et al. (2011). Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Biomarkers 16:657-62.
18. Stalenhoef AF, Davidson MH, Robinson JG, et al. (2012). Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease. Diabetes Obes Metab 14:30-9.
19. Stefan N, Fritsche A, Weikert C, et al. (2008). Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 57:2762-7.
20. Stefan N, Hennige AM, Staiger H, et al. (2006). Alpha2-Heremans- Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29:853-7. (Pubitemid 44115306)
21. Tatami R, Mabuchi H, Ueda K, et al. (1981). Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation 64:1174-84. (Pubitemid 12236146)
22. Vörös K, Gráf Jr L, Prohászka Z, et al. (2011). Serum fetuin-A in metabolic and inflammatory pathways in patients with myocardial infarction. Eur J Clin Invest 41:703-9.
23. Weikert C, Stefan N, Schulze MB, et al. (2008). Plasma fetuin - A levels and the risk of myocardial infarction and ischemic stroke. Circulation 118:2555-62.